Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results

Showing results for

The BioEscalator welcomes CardiaTec, a spin-out company from the University of Cambridge that employs computational methods to decode the biology behind cardiovascular disease.

Search results

Showing results for

BioEscalator_Brochure_2025_Digital.pdf

BioEscalator_Annual Review 2023-24.pdf

BioEscalator Gateway Criteria.pdf

Similar stories

Theolytics announces first patient dosed in the OCTOPOD-IP Trial, a US phase 1 trial with THEO-260, a novel oncolytic immunotherapy targeting ovarian cancer

Enara Bio presents first-in-class DARKFOX-Targeting bispecific T Cell engager ENA101 in oral presentation at AACR 2026, showcasing breakthrough potential in solid tumour immunotherapy

Alethio Therapeutics unveils ATX‑011, a breakthrough, mutation‑agnostic antibody for treating essential thrombocythemia – a c.$2B market, and strengthens leadership to accelerate path to IND

Explore

Information